Analysis of dysregulated long non-coding RNA expressions in glioblastoma cells


GENE, vol.590, no.1, pp.120-122, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 590 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.1016/j.gene.2016.06.024
  • Title of Journal : GENE
  • Page Numbers: pp.120-122
  • Keywords: Long non coding RNAs, Human parental brain cancer stem cell, Glioblastoma, GLIOMA


Long non coding RNAs (IcRNAs) are associated with various biological roles such as embryogenesis, stem cell biology, cellular development and present specific tissue expression profiles. Aberrant expression of IncRNAs are thought to play a critical role in the progression and development of various cancer types, including gliomas. Glioblastomas (GBM) are common and malignant primary brain tumours. Brain cancer stem cells (BCSC) are isolated from both low and high-grade tumours in adults and children, by cell fraction which express neuronal stem cell surface marker CD133. The purpose of this study was to investigate the expression profiles of IncRNAs in brain tumour cells and determine its potential biological function. For this purpose, U118MG-U87MG; GBM stem cell series were used. Human parental brain cancer cells were included as the control group; the expressions of disease related human IncRNA profiles were studied by LightCycler 480 real-time PCR. Expression profiles of 83 lncRNA genes were analyzed for a significant dysregulation, compared to the control cells. Among IncRNAs, 51 IncRNA genes down-regulated, while 8 IncRNA genes were up-regulated. PCAT-1 (2.36), MEG3 (5.34), HOTAIR (-2.48) lncRNAs showed low expression in glioblastoma compared to the human (parental) brain cancer stem cells, indicating their role as tumour suppressor genes on gliomas. As a result, significant changes for anti-cancer gene expressions were detected with disease-related human IncRNA array plates. Identification of novel target genes may lead to promising developments in human brain cancer treatment. (C) 2016 Elsevier B.V. All rights reserved.